drugset / Trial / NCT05738161
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
Phase 1
Withdrawn
Insel Gruppe AG, University Hospital Bern
Swiss National Science Foundation · collabUniversity of Bern · collab
NaSingle-groupOpen-labelTreatment
Summary
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.
Timeline
- Start
- 2023-06-21
- Primary completion
- 2024-02-27
- Completion
- 2024-02-27
Outcome
Outcome not reported
Stopped: “IMP security Issues reported by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Magrolimab | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Gemcitabine | Small molecule | — | — |